Summary

Neuroprotection Market – Scope of Report
TMR’s report on the global dementia associated with Alzheimer’s disease market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global dementia associated with Alzheimer’s disease market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global dementia associated with Alzheimer’s disease market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the dementia associated with Alzheimer’s disease market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global dementia associated with Alzheimer’s disease market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global dementia associated with Alzheimer’s disease market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global dementia associated with Alzheimer’s disease market.

The report delves into the competitive landscape of the global dementia associated with Alzheimer’s disease market. Key players operating in the global dementia associated with Alzheimer’s disease market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global dementia associated with Alzheimer’s disease market profiled in this report.

Key Questions Answered in Global dementia associated with Alzheimer’s disease Market Report
• What is the sales/revenue generated by dementia associated with Alzheimer’s disease across all regions during the forecast period?
• What are the opportunities in the global dementia associated with Alzheimer’s disease market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Neuroprotection Market – Research Objectives and Research Approach
The comprehensive report on the global dementia associated with Alzheimer’s disease market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global dementia associated with Alzheimer’s disease market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global dementia associated with Alzheimer’s disease market.

ページTOPに戻る

Table of Contents

1. Executive Summary
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Neuroprotection Market
4. Market Overview
4.1. Market Segmentation
4.1.1. Segment Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Neuroprotection Market Analysis and Forecast, 2017-2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Disease Prevalence & Incidence Rate Globally with Key Countries
5.3. COVID-19 Pandemic Impact on Industry
6. Neuroprotection Market Analysis and Forecast, By Product
6.1. Introduction and Definitions
6.2. Key Findings/Developments
6.3. Market Value Forecast, By Product, 2017–2031
6.3.1. Free Radical Trapping Agents (Antioxidants)
6.3.2. Glutamate Antagonists (Anti-excitotoxic Agents)
6.3.3. Apoptosis Inhibitors
6.3.4. Anti-inflammatory Agents
6.3.5. Neurotrophic Factors (NTFs)
6.3.6. Metal Ion Chelators
6.3.7. Stimulants
6.3.8. Others
6.4. Market Attractiveness, By Product
7. Global Neuroprotection Market Analysis and Forecast, by Application
7.1. Introduction and Definitions
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Application, 2017–2031
7.3.1. Prevention
7.3.2. Treatment
7.4. Market Attractiveness, by Application
8. Global Neuroprotection Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region, 2017–2031
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness, by Region
9. North America Neuroprotection Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, By Product, 2017–2031
9.2.1. Free Radical Trapping Agents (Antioxidants)
9.2.2. Glutamate Antagonists (Anti-excitotoxic Agents)
9.2.3. Apoptosis Inhibitors
9.2.4. Anti-inflammatory Agents
9.2.5. Neurotrophic Factors (NTFs)
9.2.6. Metal Ion Chelators
9.2.7. Stimulants
9.2.8. Others
9.3. Market Value Forecast, by Application, 2017–2031
9.3.1. Prevention
9.3.2. Treatment
9.4. Market Value Forecast, by Country, 2023–2031
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis
9.5.1. By Product
9.5.2. By Application
9.5.3. By Country
10. Europe Neuroprotection Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, By Product, 2017–2031
10.2.1. Free Radical Trapping Agents (Antioxidants)
10.2.2. Glutamate Antagonists (Anti-excitotoxic Agents)
10.2.3. Apoptosis Inhibitors
10.2.4. Anti-inflammatory Agents
10.2.5. Neurotrophic Factors (NTFs)
10.2.6. Metal Ion Chelators
10.2.7. Stimulants
10.2.8. Others
10.3. Market Value Forecast, by Application, 2017–2031
10.3.1. Prevention
10.3.2. Treatment
10.4. Market Value Forecast, by Country/Sub-region, 2017–2031
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Italy
10.4.5. Spain
10.4.6. Rest of Europe
10.5. Market Attractiveness Analysis
10.5.1. By Product
10.5.2. By Application
10.5.3. By Country/Sub-region
11. Asia Pacific Neuroprotection Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, By Product, 2017–2031
11.2.1. Free Radical Trapping Agents (Antioxidants)
11.2.2. Glutamate Antagonists (Anti-excitotoxic Agents)
11.2.3. Apoptosis Inhibitors
11.2.4. Anti-inflammatory Agents
11.2.5. Neurotrophic Factors (NTFs)
11.2.6. Metal Ion Chelators
11.2.7. Stimulants
11.2.8. Others
11.3. Market Value Forecast, by Application, 2017–2031
11.3.1. Prevention
11.3.2. Treatment
11.4. Market Value Forecast, by Country/Sub-region, 2017–2031
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Market Attractiveness Analysis
11.5.1. By Product
11.5.2. By Application
11.5.3. By Country/Sub-region
12. Latin America Neuroprotection Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, By Product, 2017–2031
12.2.1. Free Radical Trapping Agents (Antioxidants)
12.2.2. Glutamate Antagonists (Anti-excitotoxic Agents)
12.2.3. Apoptosis Inhibitors
12.2.4. Anti-inflammatory Agents
12.2.5. Neurotrophic Factors (NTFs)
12.2.6. Metal Ion Chelators
12.2.7. Stimulants
12.2.8. Others
12.3. Market Value Forecast, by Application, 2017–2031
12.3.1. Prevention
12.3.2. Treatment
12.4. Market Value Forecast, by Country/Sub-region, 2017–2031
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Market Attractiveness Analysis
12.5.1. By Product
12.5.2. By Application
12.5.3. By Country/Sub-region
13. Middle East & Africa Neuroprotection Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, By Product, 2017–2031
13.2.1. Free Radical Trapping Agents (Antioxidants)
13.2.2. Glutamate Antagonists (Anti-excitotoxic Agents)
13.2.3. Apoptosis Inhibitors
13.2.4. Anti-inflammatory Agents
13.2.5. Neurotrophic Factors (NTFs)
13.2.6. Metal Ion Chelators
13.2.7. Stimulants
13.2.8. Others
13.3. Market Value Forecast, by Application, 2017–2031
13.3.1. Prevention
13.3.2. Treatment
13.4. Market Value Forecast, by Country/Sub-region, 2017–2031
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Market Attractiveness Analysis
13.5.1. By Product
13.5.2. By Application
13.5.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player – Competition Matrix (By Tier and Size of Companies)
14.2. Market Share Analysis, by Company (2022)
14.3. Company Profiles
14.3.1. Daiichi Sankyo Company
14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2. Treatment Type Portfolio
14.3.1.3. Financial Overview
14.3.1.4. SWOT Analysis
14.3.1.5. Strategic Overview
14.3.2. Eli Lilly and Company
14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2. Treatment Type Portfolio
14.3.2.3. Financial Overview
14.3.2.4. SWOT Analysis
14.3.2.5. Strategic Overview
14.3.3. AbbVie Inc.
14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2. Treatment Type Portfolio
14.3.3.3. Financial Overview
14.3.3.4. SWOT Analysis
14.3.3.5. Strategic Overview
14.3.4. Dr. Reddy's Laboratories Ltd.
14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2. Treatment Type Portfolio
14.3.4.3. Financial Overview
14.3.4.4. SWOT Analysis
14.3.4.5. Strategic Overview
14.3.5. Teva Pharmaceutical Industries Ltd.
14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2. Treatment Type Portfolio
14.3.5.3. Financial Overview
14.3.5.4. SWOT Analysis
14.3.5.5. Strategic Overview
14.3.6. Novartis AG
14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2. Treatment Type Portfolio
14.3.6.3. Financial Overview
14.3.6.4. SWOT Analysis
14.3.6.5. Strategic Overview
14.3.7. AstraZeneca plc.
14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.7.2. Treatment Type Portfolio
14.3.7.3. Financial Overview
14.3.7.4. SWOT Analysis
14.3.7.5. Strategic Overview
14.3.8. Astrocyte Pharmaceuticals, Inc.
14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.8.2. Treatment Type Portfolio
14.3.8.3. Financial Overview
14.3.8.4. SWOT Analysis
14.3.8.5. Strategic Overview
14.3.9. F. Hoffmann-La Roche AG
14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.9.2. Treatment Type Portfolio
14.3.9.3. Financial Overview
14.3.9.4. SWOT Analysis
14.3.9.5. Strategic Overview
14.3.10. Biogen Inc.
14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.10.2. Treatment Type Portfolio
14.3.10.3. Financial Overview
14.3.10.4. SWOT Analysis
14.3.10.5. Strategic Overview